TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
TuHURA Biosciences reported Q1 2026 results with $6.3 million in cash and $5.2 million in R&D expenses, maintaining a burn rate consistent with prior periods. The company secured a $50 million non-equity credit facility from its largest stockholder, extending its cash runway into 2028 and providing capital for clinical development without immediate dilution.
Key figures
- Eps
- 0
- Revenue
- 0
- Ga expenses q1
- 2300000
- Rd expenses q1
- 5200000
- Shares outstanding
- 63600000
- Financing cash flow
- 7200000
- Cash and equivalents
- 6300000
- Credit facility size
- 50000000
- Credit facility maturity
- April 21, 2031
- Credit facility interest rate
- 12%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.